Healthcare / BiotechnologyNYSE American
$2.06
-0.05 (-2.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-2.5M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$166M
P/E
10.8x
↓EV/EBITDA
N/A
•ROE
-13.7%
↓Gross Margin
48.8%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+35.9%
FCF CAGR
—
FCF margin
-25.8%
FCF / Net income
2.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $52.7M · net income $-6.6M · FCF $-13.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $52.7M | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M | $62.9M | $54.7M | $34.2M | $21.1M | $9.2M | $4.4M | $3.5M | $0.00 | $34.9M | $8.4M | $6.6M | $388000.00 |
| Net Income | $-6.6M | $-6.6M | $2.9M | $8.3M | $-14.9M | $-27.6M | $-6.5M | $-18.3M | $-26.5M | $-83.4M | $-29.4M | $58.0M | $-29.9M | $-27.8M | $-11.6M | $-36.5M | $-29.0M | $-31.4M |
| EBITDA | $-3.0M | $-3.0M | $6.5M | $12.9M | $-10.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.08 | -0.08 | 0.04 | 0.09 | -0.31 | -0.62 | -0.22 | -1.23 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 48.8% | 48.8% | 54.5% | 64.9% | 58.9% | — | — | — | — | 19.0% | 8.7% | 83.3% | 82.1% | — | 75.4% | 17.2% | 103.3% | -821.4% |
| Operating Margin | -10.4% | -10.4% | 7.3% | 16.0% | -27.3% | -53.4% | 4.3% | -19.6% | -56.4% | -163.8% | -360.5% | -542.4% | -810.6% | — | -34.9% | -435.6% | -451.2% | -8239.4% |
| Net Margin | -12.5% | -12.5% | 5.5% | 12.7% | -31.3% | -71.9% | -10.4% | -33.4% | -77.3% | -395.9% | -319.2% | 1329.9% | -849.9% | — | -33.3% | -435.6% | -436.6% | -8103.1% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.17 | 0.17 | 0.13 | 0.78 | -3.15 | — | — | — | — | — | — | — | -0.02 | -0.09 | -1.62 | -0.25 | — | — |
| Current Ratio | 3.15 | 3.15 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-13.6M | $-13.6M | $7.4M | $-2.5M | $-25.6M | $-11.7M | $-26.8M | $-20.0M | $-8.4M | $-11.0M | $-32.9M | $-24.7M | $-30.1M | $-32.5M | $-1.4M | $-29.3M | $-46.3M | $38.3M |
| Returns | ||||||||||||||||||
| ROE | -13.7% | -13.7% | 6.8% | 24.8% | 140.3% | 457.0% | 24.1% | 26.0% | 50.0% | 283.3% | 294.9% | 533.8% | 53.9% | 103.1% | 346.1% | 140.1% | 256.1% | -197.9% |
| Valuation | ||||||||||||||||||
| P/E | 10.84 | 10.84 | 53.00 | 19.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | 24.17 | 11.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.35 | 3.35 | 3.98 | 4.27 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -1.2% | -1.2% | -18.5% | 37.5% | — | -39.0% | 15.0% | 59.7% | 62.4% | 129.1% | 110.8% | 23.9% | — | -100.0% | 315.8% | 26.3% | 1611.9% | — |
| EPS Growth | -300.0% | -300.0% | -55.6% | 129.0% | — | -181.8% | 82.1% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+32.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.04 → -0.08
Residual
+32.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.